Uplisting-Pharma-Connection to move forward. My prediction; given the sell of THC/DehydraTECH business, we now have at least one biotech pharma that we collaborate with (we will know who when filing process is done) possibly related to the bloodpressure/other health study. The financing of uplisting, will come (at least partly) from the unknown PHARMA partner.

Similar to the Altria deal; a swap with LXRP-technology vices payments of cash/ stocks/royalties from the future sale and/or research on the DehydraTECH concept. When we get one fairly good player in biotech with us, then the uplist adds up with the recent news and interviews, an actual deal is setup and will be released to public, when regulations gives clearance.

Meanwhile BAT and other projects is going on - more clarifying news will come. The CBD powder in bulk is still our primary revenue stream; growing massive on a 500% + increase quarter to quarter, so far. The patent portfolio has grown during the year - one of the patents is setup for the coming pharma partner = LXRP will gain more credibility as well as a strong partner in 2021.

It might be a European biotech, since we recently was granted that patent. The patents that are granted are possible to monetize now; and patents can be very valuable in the hands of the right matching partner (-s) to Lexaria - this will be a major catalyst for the stock price and open new doors for us.